Immuno-oncology and cell therapy seminar
Wednesday June 14, 2017
11:30 - 14:00
IRIC- Pavillon Jean-Coutu, Salle S1-151
A – Immuno-Oncology’s Signal-to-Noise Problem: Developing Proof of Relevance for Novel MOAs
Abstract : Immunotherapy has over the past 5 or so years gone from an exclusion on BioPharma’s external innovation list in searches for licensing or M&A opportunities to now being the hottest space that perhaps the industry has ever seen in Oncology (and maybe any therapeutic area). This presentation will provide a context and lay out some of the challenges, as well some of the ways that newcos can think about strategizing in the new frontier that is Immuno-Oncology.
B – The One Shot Cure: Developing and Commercializing Genetic Therapies
Abstract: Gene and cell therapies have been among the hottest biotechnology sectors for IPOs and licensing deals in recent years. High valuations signify an inflection in the validation of gene transfer and cell section technologies, as well as, prioritizing tractable disease indications for which evidence of disease modification, if not cures, can be proven. Commercializing such “complex therapies” necessitates pioneering new regulatory strategies, manufacturing processes, and logistical and reimbursement infrastructure in order to facilitate delivery of individualized therapies to highly fragmented markets. Join us in the discussion on the recent progress and outstanding issues in realizing the promise of gene and cell therapies.